|
More
Basic Research Reports
| F19
Survives the Upper GI Tract |
Lactobacillus F19 has been
shown to be an effective probiotic culture. It can survive the upper GI
tract, which is not surprising considering F19 can grow in the presence
of human bile. MRS media was supplemented with 0.3, 0.5, and 5.0 %
human bile and was inoculated with Lactobacillus
F19 (Figure 8). F19 grew in all
concentrations of bile tested. In another experiment, F19 even survived
for 2 hours in MRS broth with 20% ox gall added. It also has been shown
that F19 grows in the presence of bile without deconjugating bile salts.
In addition, Ljungh et al (2002) showed
that F19 could survive in lower
pH ranges. Lactobacillus F19
was added to MRS broth adjusted to a pH of 2.5 using 1 M HCl. F19
survived for one hour when incubated at 30oC (86oF).
Figure
8. Fecal
counts of Lactobacillus
F19
in elderly treatment participants.
Knowing
that the adverse environment of
the stomach was no obstacle for
Lactobacillus F19, Ljungh et al also testing the
binding affinities of the culture.
It was determined that F19 had a high surface hydrophobicity. It has
excellent
adhesion to mucin, collagens I and III,
fibrinogen, heparin, and fibronectin.
Kapczynski et al (2000) correlated
fibronectin binding ability to adherence
of bacteria to intestinal
lining cells. Thus, F19 has the ability to colonize the
GI tract.
|
| For More Information... Contact Us |
| Medipharm believes
we have considerable information
detailing the research and development efforts necessary to launch Lactobacillus
F19 into the probiotic marketplace. This
documentation makes F19 one of the most completely-researched strains
available
for incorporation into functional foods and supplements.
Copies of the studies summarized and
presented here, as well as numerous other
published
reports, are available
on request. |
We
encourage you to contact
us in order to
provide all information necessary to allow for an educated decision
when it
comes to selecting a probiotic culture.
The technology represented here has been sufficient to grant a U.S
patent for Lactobacillus F19 in July of 2003 (US Patent Number
6,599,504). When it comes to beneficial
bacteria for better health, consider Medipharm. |
|
For general inquiries, more information,
copies of documented research, or answers to commonly asked questions,
contact us!
Tom Wiersum, Product Manager, Food &
Nutrition
Call 1-800-397-5689 Ext 209 or
e-mail inquiries to: twiersum@medipharmusa.com
|
|